Pay vs Performance Disclosure, Table

Pay Versus Performance

As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive “compensation actually paid” and certain financial performance of the Company. For further information regarding our pay for performance philosophy and how we align executive compensation with the Company’s performance, refer to the “Compensation Discussion and Analysis” on page 50.

									Value of Initial Fixed $100 Investment Based on:
Year	Summary Compensation Table Total for Mr. O’Day⁽¹⁾		Compensation Actually Paid to Mr. O’Day⁽²⁾		Average Summary Compensation Table Total for Other NEOs⁽³⁾		Average Compensation Actually Paid to Other NEOs⁽⁴⁾		Total Shareholder Return⁽⁵⁾		Peer Group Total Shareholder Return⁽⁶⁾		Net Income (in millions)⁽⁷⁾		Net Product Revenue (in millions)⁽⁸⁾
2024	$	23,689,392	$	44,785,379	$	7,725,458	$	14,186,970	$	174	$	118	$	480	$	28,610
2023	$	22,607,690	$	15,483,783	$	7,588,163	$	5,469,137	$	147	$	119	$	5,613	$	26,934
2022	$	21,621,253	$	54,965,255	$	7,874,828	$	18,182,586	$	150	$	114	$	4,566	$	26,982
2021	$	19,229,466	$	31,485,348	$	6,279,776	$	9,693,178	$	121	$	126	$	6,201	$	27,008
2020	$	18,998,095	$	16,117,322	$	6,616,768	$	6,126,435	$	93	$	126	$	89	$	24,355

⁽¹⁾
⁽²⁾

⁽³⁾
⁽⁵⁾
⁽⁴⁾
⁽⁶⁾
⁽⁷⁾
⁽⁸⁾

⁽¹⁾	The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.

⁽²⁾

The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:

Year	Summary Compensation Table Total for Mr. O’Day		Less: Summary Compensation Table Reported Value of Equity Awards^(a)		Plus: Equity Award Adjustments^(b)		Equals: Compensation Actually Paid to Mr. O’Day
2024	$	23,689,392	$	16,551,827	$	37,647,814	$	44,785,379
2023	$	22,607,690	$	15,615,056	$	8,491,149	$	15,483,783
2022	$	21,621,253	$	14,353,915	$	47,697,917	$	54,965,255
2021	$	19,229,466	$	13,139,064	$	25,394,946	$	31,485,348
2020	$	18,998,095	$	11,513,097	$	8,632,324	$	16,117,322

^(a)	Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
^(b)	The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:

Year	Year End Fair Value of Equity Awards Granted during the Year		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested during the Year			Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Equity Award Adjustments
2024	$	23,956,270	$	13,333,936		$	(1,033,888	)	$	1,391,496	$	37,647,814
2023	$	12,525,814	$	(2,481,113	)	$	(2,859,625	)	$	1,306,073	$	8,491,149
2022	$	34,153,918	$	14,183,571		$	(1,966,582	)	$	1,327,010	$	47,697,917
2021	$	17,162,219	$	6,011,125		$	707,262		$	1,514,340	$	25,394,946
2020	$	8,885,442	$	(1,693,496	)	$	409,911		$	1,030,467	$	8,632,324

⁽³⁾

The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2024, 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.

⁽⁴⁾

The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:

Year	Average Reported Summary Compensation Table Total for Other NEOs		Less: Summary Compensation Table Average Reported Value of Equity Awards		Plus: Average Equity Award Adjustments^(a)		Equals: Average Compensation Actually Paid to Other NEOs
2024	$	7,725,458	$	4,828,738	$	11,290,250	$	14,186,970
2023	$	7,588,163	$	4,809,225	$	2,690,199	$	5,469,137
2022	$	7,874,828	$	4,961,052	$	15,268,810	$	18,182,586
2021	$	6,279,776	$	3,625,534	$	7,038,936	$	9,693,178
2020	$	6,616,768	$	3,087,064	$	2,596,731	$	6,126,435

^(a)	The amounts deducted or added in calculating the total average equity award adjustments are as follows:

Year	Average Year End Fair Value of Equity Awards Granted During the Year		Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Average Equity Award Adjustments
2024	$	6,878,321	$	4,260,282		$	(282,467	)	$	434,114	$	11,290,250
2023	$	3,955,902	$	(789,322	)	$	(879,498	)	$	403,117	$	2,690,199
2022	$	11,751,514	$	3,365,229		$	(289,102	)	$	441,169	$	15,268,810
2021	$	4,989,853	$	1,461,574		$	271,571		$	315,938	$	7,038,936
2020	$	2,488,166	$	(365,446	)	$	269,145		$	204,866	$	2,596,731

⁽⁵⁾

Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.

⁽⁶⁾	The peer group used for this purpose is Nasdaq Biotechnology Index.

⁽⁷⁾

The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets acquired from Immunomedics, Inc. Our 2024 net income included $4.2 billion partial impairment charges related to certain IPR&D assets acquired from Immunomedics, Inc.

⁽⁸⁾

The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2024 product sales of $28,610 increased by 6% compared to the same period in 2023, with higher HIV, Liver Disease, and Oncology sales.

Company Selected Measure Name

Net Product Revenue

Named Executive Officers, Footnote [Text Block]

⁽¹⁾	The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.

(3)The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2024, 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.

Peer Group Issuers, Footnote

⁽⁶⁾	The peer group used for this purpose is Nasdaq Biotechnology Index.

PEO Total Compensation Amount

^[1]

$ 23,689,392

$ 22,607,690

$ 21,621,253

$ 19,229,466

$ 18,998,095

PEO Actually Paid Compensation Amount

^[2]

$ 44,785,379

15,483,783

54,965,255

31,485,348

16,117,322

Adjustment To PEO Compensation, Footnote

⁽²⁾

Year	Summary Compensation Table Total for Mr. O’Day		Less: Summary Compensation Table Reported Value of Equity Awards^(a)		Plus: Equity Award Adjustments^(b)		Equals: Compensation Actually Paid to Mr. O’Day
2024	$	23,689,392	$	16,551,827	$	37,647,814	$	44,785,379
2023	$	22,607,690	$	15,615,056	$	8,491,149	$	15,483,783
2022	$	21,621,253	$	14,353,915	$	47,697,917	$	54,965,255
2021	$	19,229,466	$	13,139,064	$	25,394,946	$	31,485,348
2020	$	18,998,095	$	11,513,097	$	8,632,324	$	16,117,322

^(a)	Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
^(b)	The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:

Year	Year End Fair Value of Equity Awards Granted during the Year		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested during the Year			Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Equity Award Adjustments
2024	$	23,956,270	$	13,333,936		$	(1,033,888	)	$	1,391,496	$	37,647,814
2023	$	12,525,814	$	(2,481,113	)	$	(2,859,625	)	$	1,306,073	$	8,491,149
2022	$	34,153,918	$	14,183,571		$	(1,966,582	)	$	1,327,010	$	47,697,917
2021	$	17,162,219	$	6,011,125		$	707,262		$	1,514,340	$	25,394,946
2020	$	8,885,442	$	(1,693,496	)	$	409,911		$	1,030,467	$	8,632,324

Non-PEO NEO Average Total Compensation Amount

^[3]

$ 7,725,458

7,588,163

7,874,828

6,279,776

6,616,768

Non-PEO NEO Average Compensation Actually Paid Amount

^[4]

$ 14,186,970

5,469,137

18,182,586

9,693,178

6,126,435

Adjustment to Non-PEO NEO Compensation Footnote

⁽⁴⁾

Year	Average Reported Summary Compensation Table Total for Other NEOs		Less: Summary Compensation Table Average Reported Value of Equity Awards		Plus: Average Equity Award Adjustments^(a)		Equals: Average Compensation Actually Paid to Other NEOs
2024	$	7,725,458	$	4,828,738	$	11,290,250	$	14,186,970
2023	$	7,588,163	$	4,809,225	$	2,690,199	$	5,469,137
2022	$	7,874,828	$	4,961,052	$	15,268,810	$	18,182,586
2021	$	6,279,776	$	3,625,534	$	7,038,936	$	9,693,178
2020	$	6,616,768	$	3,087,064	$	2,596,731	$	6,126,435

^(a)	The amounts deducted or added in calculating the total average equity award adjustments are as follows:

Year	Average Year End Fair Value of Equity Awards Granted During the Year		Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Average Equity Award Adjustments
2024	$	6,878,321	$	4,260,282		$	(282,467	)	$	434,114	$	11,290,250
2023	$	3,955,902	$	(789,322	)	$	(879,498	)	$	403,117	$	2,690,199
2022	$	11,751,514	$	3,365,229		$	(289,102	)	$	441,169	$	15,268,810
2021	$	4,989,853	$	1,461,574		$	271,571		$	315,938	$	7,038,936
2020	$	2,488,166	$	(365,446	)	$	269,145		$	204,866	$	2,596,731

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid Versus TSR 2020 – 2024

Compensation Actually Paid vs. Net Income

Compensation Actually Paid Versus Net Income 2020 – 2024

Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid Versus Net Revenue 2020 – 2024

Total Shareholder Return Vs Peer Group

Compensation Actually Paid Versus TSR 2020 – 2024

Tabular List, Table

Financial Performance Measures

As described in greater detail in “Executive Compensation – Compensation Discussion and Analysis” on page 50, our executive compensation program reflects a pay-for-performance philosophy, with a focus not only on the successful progression of research programs, clinical trials and the launch of new products but also on performance across a range of shorter-term metrics that advance our long-term strategy and longer-term value creation for our stockholders. The metrics that we use for both our long-term and short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our company for our stockholders. As required by Item 402(v), the most important financial performance measures used by the Company to link compensation actually paid to the NEOs, for the most recently completed fiscal year, to the Company’s performance are as follows:

	a.	Net Product Revenue
	b.	Relative TSR
	c.	Non-GAAP Operating Income

Total Shareholder Return Amount

^[5]

$ 174

147

150

121

Peer Group Total Shareholder Return Amount

^[6]

118

119

114

126

Net Income (Loss) Attributable to Parent

^[7]

$ 480,000,000

$ 5,613,000,000

$ 4,566,000,000

$ 6,201,000,000

$ 89,000,000

Company Selected Measure Amount

^[8]

28,610,000,000

26,934,000,000

26,982,000,000

27,008,000,000

24,355,000,000

PEO Name

Mr. O’Day

Additional 402(v) Disclosure

Measure [Axis]: 1

Measure Name

Net Product Revenue

Measure [Axis]: 2

Measure Name

Relative TSR

Measure [Axis]: 3

PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]

Measure Name

Non-GAAP Operating Income

PEO [Member] | Equity Awards Adjustments [Member]

^[9]

$ 16,551,827

$ 15,615,056

$ 14,353,915

$ 13,139,064

$ 11,513,097

PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]

^[10]

37,647,814

8,491,149

47,697,917

25,394,946

8,632,324

PEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]

23,956,270

12,525,814

34,153,918

17,162,219

8,885,442

PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]

13,333,936

(2,481,113)

14,183,571

6,011,125

(1,693,496)

PEO [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]

(1,033,888)

(2,859,625)

(1,966,582)

707,262

409,911

Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]

1,391,496

1,306,073

1,327,010

1,514,340

1,030,467

Non-PEO NEO [Member] | Equity Awards Adjustments [Member]

4,828,738

4,809,225

4,961,052

3,625,534

3,087,064

Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]

^[11]

11,290,250

2,690,199

15,268,810

7,038,936

2,596,731

Non-PEO NEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]

6,878,321

3,955,902

11,751,514

4,989,853

2,488,166

Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]

4,260,282

(789,322)

3,365,229

1,461,574

(365,446)

Non-PEO NEO [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]

(282,467)

(879,498)

(289,102)

271,571

269,145

Awards Close in Time to MNPI Disclosures [Table]

$ 434,114

$ 403,117

$ 441,169

$ 315,938

$ 204,866

[1]	The dollar amounts reported are the amounts reported in the “Total” column of the Summary Compensation Table for our Chairman and Chief Executive Officer, Mr. O’Day.
[2]	The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:
[3]	The dollar amounts reported represent the average of the amounts reported for our NEOs as a group (excluding our CEO) in the “Total” column of the Summary Compensation Table in each applicable year. The NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2024, 2023 and 2022, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Deborah H. Telman; and (ii) for 2021 and 2020, Andrew D. Dickinson, Johanna Mercier, Merdad V. Parsey and Brett A. Pletcher.
[4]	The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
[5]	Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end of each year shown and the beginning of the measurement period by our share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2019.
[6]	The peer group used for this purpose is Nasdaq Biotechnology Index.
[7]	The dollar amounts reported represent the amount of net income reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Our 2022 net income included a $2.7 billion partial impairment charge related to certain IPR&D assets acquired from Immunomedics, Inc. Our 2024 net income included $4.2 billion partial impairment charges related to certain IPR&D assets acquired from Immunomedics, Inc.
[8]	The dollar amounts reported represent the amount of net product sales revenue reflected in our Consolidated Statements of Income included in our Annual Report on Form 10-K for the applicable year. Total full year 2024 product sales of $28,610 increased by 6% compared to the same period in 2023, with higher HIV, Liver Disease, and Oncology sales.
[9]	Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
[10]	The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
[11]	The amounts deducted or added in calculating the total average equity award adjustments are as follows:

Award Timing Disclosure

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Mar. 10, 2024

USD ($)

$ / shares

Award Timing MNPI Disclosure

The Compensation and Talent Committee generally approves the target value of annual equity awards for the Company’s executive officers, including each of the Named Executive Officers, at its regularly scheduled meeting in late January or early February of each year, with a grant date to be effective on March 10^th, which is generally following the filing of our Annual Report on Form 10-K for the prior year. Annual equity awards to other company employees are typically approved by our CEO with a grant date of March 10th as well. Additionally, employees may enroll to purchase shares of the Company’s common stock under the terms of the Gilead Sciences, Inc. Employee Stock Purchase Plan, with purchase dates generally in February and August of each year. In special circumstances, including the hiring or promotion of an individual or where the Committee or its authorized delegate determines it is in the best interest of the Company, the Committee or its delegate may approve grants throughout the year, with such grants effective on the 10^th day of each calendar month or at other times determined to be appropriate. The Company may change these practices in the future. The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Consistent with the above-described practice, on March 10, 2024, the Committee granted our Named Executive Officers annual equity awards including stock options, restricted stock units and performance shares. This pre-approved grant was made four days before the Company filed a Form 8-K disclosing that Kevin E. Lofton had notified the Board of his decision to retire from the Board, effective as of the conclusion of his term at Gilead’s next annual meeting of stockholders held on May 8, 2024.

Due to this Form 8-K event, as required by SEC rules, the table below sets forth certain information about the annual stock option grants made to our Named Executive Officers.

Name	Grant Date	Number of Securities Underlying the Award		Exercise Price of the Award ($/Sh)		Grant Date Fair Value of the Award		Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information⁽¹⁾
Daniel P. O’Day	March 10, 2024		279,130	$	75.12	$	4,125,011		(2.96)	%
Andrew D. Dickinson	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Johanna Mercier	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Merdad V. Parsey, M.D., Ph.D.	March 10, 2024		89,660	$	75.12	$	1,325,004		(2.96)	%
Deborah H. Telman	March 10, 2024		54,980	$	75.12	$	812,500		(2.96)	%

⁽¹⁾

Reflects the percentage change in the closing market price of our common stock between the trading day ending immediately prior to the Form 8-K filing ($75.94 on March 13, 2024) and the trading day beginning immediately following the disclosure of material nonpublic information ($73.69 on March 15, 2024).

Award Timing Method

Award Timing Predetermined

true

Award Timing, How MNPI Considered

The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

MNPI Disclosure Timed for Compensation Value

false

Disclosure - Award Timing Disclosure

Name	Grant Date	Number of Securities Underlying the Award		Exercise Price of the Award ($/Sh)		Grant Date Fair Value of the Award		Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information⁽¹⁾
Daniel P. O’Day	March 10, 2024		279,130	$	75.12	$	4,125,011		(2.96)	%
Andrew D. Dickinson	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Johanna Mercier	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Merdad V. Parsey, M.D., Ph.D.	March 10, 2024		89,660	$	75.12	$	1,325,004		(2.96)	%
Deborah H. Telman	March 10, 2024		54,980	$	75.12	$	812,500		(2.96)	%

Adjustment To PEO Compensation, Footnote [Text Block]

⁽²⁾

Year	Summary Compensation Table Total for Mr. O’Day		Less: Summary Compensation Table Reported Value of Equity Awards^(a)		Plus: Equity Award Adjustments^(b)		Equals: Compensation Actually Paid to Mr. O’Day
2024	$	23,689,392	$	16,551,827	$	37,647,814	$	44,785,379
2023	$	22,607,690	$	15,615,056	$	8,491,149	$	15,483,783
2022	$	21,621,253	$	14,353,915	$	47,697,917	$	54,965,255
2021	$	19,229,466	$	13,139,064	$	25,394,946	$	31,485,348
2020	$	18,998,095	$	11,513,097	$	8,632,324	$	16,117,322

^(a)	Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
^(b)	The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:

Year	Year End Fair Value of Equity Awards Granted during the Year		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested during the Year			Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Equity Award Adjustments
2024	$	23,956,270	$	13,333,936		$	(1,033,888	)	$	1,391,496	$	37,647,814
2023	$	12,525,814	$	(2,481,113	)	$	(2,859,625	)	$	1,306,073	$	8,491,149
2022	$	34,153,918	$	14,183,571		$	(1,966,582	)	$	1,327,010	$	47,697,917
2021	$	17,162,219	$	6,011,125		$	707,262		$	1,514,340	$	25,394,946
2020	$	8,885,442	$	(1,693,496	)	$	409,911		$	1,030,467	$	8,632,324

PEO Name

Mr. O’Day

Adjustment to Non-PEO NEO Compensation Footnote [Text Block]

⁽⁴⁾

Year	Average Reported Summary Compensation Table Total for Other NEOs		Less: Summary Compensation Table Average Reported Value of Equity Awards		Plus: Average Equity Award Adjustments^(a)		Equals: Average Compensation Actually Paid to Other NEOs
2024	$	7,725,458	$	4,828,738	$	11,290,250	$	14,186,970
2023	$	7,588,163	$	4,809,225	$	2,690,199	$	5,469,137
2022	$	7,874,828	$	4,961,052	$	15,268,810	$	18,182,586
2021	$	6,279,776	$	3,625,534	$	7,038,936	$	9,693,178
2020	$	6,616,768	$	3,087,064	$	2,596,731	$	6,126,435

^(a)	The amounts deducted or added in calculating the total average equity award adjustments are as follows:

Year	Average Year End Fair Value of Equity Awards Granted During the Year		Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Average Equity Award Adjustments
2024	$	6,878,321	$	4,260,282		$	(282,467	)	$	434,114	$	11,290,250
2023	$	3,955,902	$	(789,322	)	$	(879,498	)	$	403,117	$	2,690,199
2022	$	11,751,514	$	3,365,229		$	(289,102	)	$	441,169	$	15,268,810
2021	$	4,989,853	$	1,461,574		$	271,571		$	315,938	$	7,038,936
2020	$	2,488,166	$	(365,446	)	$	269,145		$	204,866	$	2,596,731

Peer Group Issuers, Footnote [Text Block]

⁽⁶⁾	The peer group used for this purpose is Nasdaq Biotechnology Index.

O Day [Member]

Awards Close in Time to MNPI Disclosures [Table]

Awards Close in Time to MNPI Disclosures, Individual Name

Daniel P. O’Day

279,130

$ 75.12

$ 4,125,011

Awards Close in Time to MNPI Disclosures [Table]

(0.0296)

Dickinson [Member]

Awards Close in Time to MNPI Disclosures, Individual Name

Andrew D. Dickinson

87,970

$ 75.12

$ 1,300,029

Awards Close in Time to MNPI Disclosures [Table]

(0.0296)

Mercier [Member]

Awards Close in Time to MNPI Disclosures, Individual Name

Johanna Mercier

87,970

$ 75.12

$ 1,300,029

Awards Close in Time to MNPI Disclosures [Table]

(0.0296)

Parsey [Member]

Awards Close in Time to MNPI Disclosures, Individual Name

Merdad V. Parsey, M.D., Ph.D.

89,660

$ 75.12

$ 1,325,004

Awards Close in Time to MNPI Disclosures [Table]

(0.0296)

Telman [Member]

Awards Close in Time to MNPI Disclosures, Individual Name

Deborah H. Telman

54,980

$ 75.12

$ 812,500